Immunocore (NASDAQ:IMCR) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunocore (NASDAQ:IMCR) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $100.00 target price on the stock.

A number of other brokerages have also commented on IMCR. JPMorgan Chase & Co. raised their price target on Immunocore from $60.00 to $70.00 and gave the stock an overweight rating in a research note on Wednesday, March 20th. Canaccord Genuity Group raised their price target on Immunocore from $63.00 to $67.00 and gave the stock a hold rating in a research note on Thursday, May 9th. Guggenheim reaffirmed a buy rating and issued a $92.00 price target on shares of Immunocore in a research note on Tuesday, April 23rd. Leerink Partnrs reissued an outperform rating on shares of Immunocore in a research report on Monday, April 29th. Finally, Needham & Company LLC reissued a buy rating and set a $81.00 price objective on shares of Immunocore in a research report on Friday. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, Immunocore has an average rating of Moderate Buy and a consensus target price of $81.85.

Immunocore Price Performance

Shares of IMCR stock traded down $1.93 during trading on Friday, hitting $46.05. The company had a trading volume of 5,140,250 shares, compared to its average volume of 656,852. The company has a quick ratio of 5.94, a current ratio of 5.96 and a debt-to-equity ratio of 1.22. The stock’s 50-day moving average is $58.46 and its two-hundred day moving average is $61.88. Immunocore has a 52 week low of $41.01 and a 52 week high of $76.98.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The business had revenue of $70.30 million for the quarter, compared to the consensus estimate of $70.72 million. During the same quarter in the previous year, the business earned ($0.35) earnings per share. The firm’s revenue was up 27.6% on a year-over-year basis. Research analysts predict that Immunocore will post -1.88 EPS for the current fiscal year.

Institutional Trading of Immunocore

Institutional investors and hedge funds have recently made changes to their positions in the business. Exchange Traded Concepts LLC boosted its stake in shares of Immunocore by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock worth $181,000 after acquiring an additional 674 shares during the last quarter. JGP Global Gestao de Recursos Ltda. acquired a new position in Immunocore during the fourth quarter worth $230,000. NEOS Investment Management LLC acquired a new position in Immunocore during the fourth quarter worth $262,000. China Universal Asset Management Co. Ltd. boosted its stake in Immunocore by 366.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,900 shares of the company’s stock worth $266,000 after buying an additional 3,064 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. boosted its stake in Immunocore by 26.6% during the third quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock worth $389,000 after buying an additional 1,572 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.